日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer

FDA批准摘要:帕博利珠单抗用于治疗HER2阳性胃癌

Casak, Sandra J; Zhang, Yiming; Song, Chi; Mishra-Kalyani, Pallavi S; Tang, Shenghui; Auth, Doris; de Claro, R Angelo; Pazdur, Richard; Lemery, Steven J

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

FDA批准摘要:呋喹替尼用于治疗难治性转移性结直肠癌

Fusco, Michael J; Casak, Sandra J; Mushti, Sirisha L; Cheng, Joyce; Christmas, Brian J; Thompson, Matthew D; Fu, Wentao; Wang, Hezhen; Yoon, Miyoung; Yang, Yuching; Moore, Jason N; Bi, Youwei; Nan, Yang; Long, Craig E; Auth, Doris; Rahman, Nam A; Tang, Shenghui; Pazdur, Richard; Fashoyin-Aje, Lola A; Kluetz, Paul G; Lemery, Steven J

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

FDA批准摘要:度伐利尤单抗和帕博利珠单抗,用于治疗胆道癌的免疫检查点抑制剂

Casak, Sandra J; Kumar, Vaibhav; Song, Chi; Yuan, Mengdie; Amatya, Anup K; Cheng, Joyce; Mishra-Kalyani, Pallavi S; Tang, Shenghui; Lemery, Steven J; Auth, Doris; Davis, Gina; Kluetz, Paul G; Pazdur, Richard; Fashoyin-Aje, Lola A

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

FDA批准摘要:Futibatinib用于治疗不可切除的晚期或转移性、化疗难治性肝内胆管癌,伴有FGFR2融合或其他重排

Gandhy, Shruti U; Casak, Sandra J; Mushti, Sirisha L; Cheng, Joyce; Subramaniam, Sriram; Zhao, Hong; Zhao, Miao; Bi, Youwei; Liu, Guansheng; Fan, Jianghong; Adeniyi, Oluseyi; Charlab, Rosane; Kufrin, Dubravka; Thompson, Matthew D; Jarrell, Kristin; Auth, Doris; Lemery, Steven J; Pazdur, Richard; Kluetz, Paul G; Fashoyin-Aje, Lola A

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

FDA批准摘要:图卡替尼联合曲妥珠单抗用于治疗晚期不可切除或转移性、化疗难治性、HER2阳性、RAS野生型结直肠癌

Casak, Sandra J; Horiba, M Naomi; Yuan, Mengdie; Cheng, Joyce; Lemery, Steven J; Shen, Yuan Li; Fu, Wentao; Moore, Jason N; Li, Yangbing; Bi, Youwei; Auth, Doris; Fesenko, Nataliya; Kluetz, Paul G; Pazdur, Richard; Fashoyin-Aje, Lola A

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

抗生素与接受靶向或免疫疗法治疗肝细胞癌患者的不良肿瘤结局之间的关联

Pinato, David J; Li, Xiaoxue; Mishra-Kalyani, Pallavi; D'Alessio, Antonio; Fulgenzi, Claudia A M; Scheiner, Bernhard; Pinter, Matthias; Wei, Guo; Schneider, Julie; Rivera, Donna R; Pazdur, Richard; Theoret, Marc R; Casak, Sandra; Lemery, Steven; Fashoyin-Aje, Lola; Cortellini, Alessio; Pelosof, Lorraine

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

FDA批准摘要:Ivosidenib用于治疗伴有IDH1突变的晚期不可切除或转移性、化疗难治性胆管癌患者

Casak, Sandra J; Pradhan, Shan; Fashoyin-Aje, Lola A; Ren, Yi; Shen, Yuan-Li; Xu, Yuan; Chow, Edwin Chiu Yuen; Xiong, Ye; Zirklelbach, Jeanne Fourie; Liu, Jiang; Charlab, Rosane; Pierce, William F; Fesenko, Nataliya; Beaver, Julia A; Pazdur, Richard; Kluetz, Paul G; Lemery, Steven J

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

FDA批准摘要:纳武利尤单抗用于完全切除食管/胃食管交界处癌且存在残留病理病灶的成年患者的辅助治疗

Horiba, M Naomi; Casak, Sandra J; Mishra-Kalyani, Pallavi S; Roy, Pourab; Beaver, Julia A; Pazdur, Richard; Kluetz, Paul G; Lemery, Steven J; Fashoyin-Aje, Lola A

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

FDA批准摘要:帕博利珠单抗用于一线治疗MSI-H/dMMR晚期不可切除或转移性结直肠癌患者

Casak, Sandra J; Marcus, Leigh; Fashoyin-Aje, Lola; Mushti, Sirisha L; Cheng, Joyce; Shen, Yuan-Li; Pierce, William F; Her, Leah; Goldberg, Kirsten B; Theoret, Marc R; Kluetz, Paul G; Pazdur, Richard; Lemery, Steven J

Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy

纳武利尤单抗治疗既往接受过氟尿嘧啶和铂类化疗的不可切除的晚期、复发性或转移性食管鳞状细胞癌患者的获益风险总结

Pelosof, Lorraine; Saung, May Tun; Donoghue, Martha; Casak, Sandra; Mushti, Sirisha; Cheng, Joyce; Jiang, Xiling; Liu, Jiang; Zhao, Hong; Khazraee, Maryam; Goldberg, Kirsten B; Theoret, Marc; Lemery, Steven; Pazdur, Richard; Fashoyin-Aje, Lola